LON:OXB - Oxford Biomedica Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 1,707.50
  • Forecasted Upside: 75.49 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
GBX 973
▼ -2 (-0.21%)

This chart shows the closing price for OXB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oxford Biomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OXB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OXB

Analyst Price Target is GBX 1,707.50
▲ +75.49% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is GBX 1,707.50, with a high forecast of GBX 2,150 and a low forecast of GBX 1,200. The average price target represents a 75.49% upside from the last price of GBX 973.

This chart shows the closing price for OXB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Oxford Biomedica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
10/19/2021Peel HuntReiterated RatingBuyGBX 2,150
5/19/2021Liberum CapitalBoost Price TargetBuyGBX 1,300 ➝ GBX 1,330
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Peel HuntReiterated RatingBuyGBX 1,150
5/18/2021Numis SecuritiesReiterated RatingBuyGBX 1,200
4/15/2021Liberum CapitalReiterated RatingBuyGBX 1,300 ➝ GBX 1,280
4/6/2021Liberum CapitalReiterated RatingBuyGBX 1,280
8/3/2020Liberum CapitalReiterated RatingBuy
7/31/2020Peel HuntReiterated RatingBuy
7/21/2020Peel HuntReiterated RatingBuy
7/21/2020Liberum CapitalReiterated RatingBuy
7/2/2020Peel HuntReiterated RatingBuy
6/24/2020Liberum CapitalLower Price TargetBuyGBX 1,090 ➝ GBX 1,050
6/19/2020Peel HuntReiterated RatingBuyGBX 1,050 ➝ GBX 1,000
6/8/2020Peel HuntReiterated RatingBuyGBX 1,060 ➝ GBX 1,050
6/8/2020Liberum CapitalReiterated RatingBuy
6/1/2020Peel HuntReiterated RatingBuy
5/29/2020Liberum CapitalReiterated RatingBuy
5/14/2020Jefferies Financial GroupBoost Price TargetHoldGBX 700 ➝ GBX 730
5/13/2020Peel HuntReiterated RatingBuy
5/13/2020Liberum CapitalReiterated RatingBuy
5/6/2020Liberum CapitalReiterated RatingBuy
5/1/2020Peel HuntReiterated RatingBuy
4/28/2020Liberum CapitalBoost Price TargetBuyGBX 860 ➝ GBX 1,090
4/24/2020Peel HuntReiterated RatingBuy
4/8/2020Liberum CapitalReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
3/18/2020Peel HuntReiterated RatingBuy
3/18/2020Liberum CapitalReiterated RatingBuy
3/5/2020Peel HuntReiterated RatingBuy
2/13/2020Peel HuntReiterated RatingBuy
2/5/2020Peel HuntReiterated RatingBuy
1/29/2020Liberum CapitalReiterated RatingBuy
1/27/2020Peel HuntReiterated RatingBuy
1/13/2020Liberum CapitalBoost Price TargetBuyGBX 810 ➝ GBX 860
1/10/2020Peel HuntReiterated RatingBuy
12/19/2019Peel HuntReiterated RatingBuy
12/19/2019Liberum CapitalReiterated RatingBuy
12/5/2019Liberum CapitalReiterated RatingBuy
12/5/2019Peel HuntReiterated RatingBuy
11/15/2019Liberum CapitalReiterated RatingBuy
11/4/2019Peel HuntReiterated RatingBuy
10/22/2019Peel HuntReiterated RatingBuy
10/22/2019Liberum CapitalReiterated RatingBuy
9/30/2019Liberum CapitalInitiated CoverageBuyGBX 810
9/2/2019Peel HuntReiterated RatingBuy
8/1/2019Peel HuntReiterated RatingBuy
7/3/2019Peel HuntReiterated RatingBuy
6/26/2019Peel HuntReiterated RatingBuy
6/26/2019Peel HuntReiterated RatingBuy
6/4/2019Peel HuntReiterated RatingBuy
5/14/2019Peel HuntReiterated RatingBuy
5/2/2019Peel HuntReiterated RatingBuy
4/23/2019Peel HuntInitiated CoverageBuy
4/2/2019Peel HuntReiterated RatingBuy
3/12/2019Peel HuntReiterated RatingBuy
1/30/2019Peel HuntReiterated RatingBuy
1/17/2019Peel HuntReiterated RatingBuy
1/7/2019Peel HuntReiterated RatingBuy
12/24/2018Peel HuntReiterated RatingBuy
12/4/2018Peel HuntReiterated RatingBuy
11/23/2018Peel HuntReiterated RatingBuy
11/1/2018Peel HuntReiterated RatingBuy
10/25/2018Peel HuntReiterated RatingBuy
10/3/2018Peel HuntReiterated RatingBuy
9/13/2018Peel HuntReiterated RatingBuy
9/4/2018Peel HuntReiterated RatingBuy
8/28/2018Peel HuntReiterated RatingBuy
8/1/2018Peel HuntReiterated RatingBuy
7/18/2018Peel HuntReiterated RatingBuy
7/3/2018Peel HuntReiterated RatingBuy
6/13/2018Jefferies Financial GroupDowngradeHold
5/31/2018Peel HuntReiterated RatingBuy
5/1/2018Peel HuntReiterated RatingBuyGBX 16
4/19/2018Peel HuntReiterated RatingBuyGBX 16
4/4/2018Peel HuntReiterated RatingBuyGBX 16
3/15/2018Peel HuntBoost Price TargetBuyGBX 13 ➝ GBX 16
3/1/2018Peel HuntReiterated RatingBuyGBX 13
2/15/2018Peel HuntReiterated RatingBuyGBX 13
2/1/2018Peel HuntReiterated RatingBuyGBX 13
1/8/2018Peel HuntReiterated RatingBuyGBX 13
10/31/2017Peel HuntReiterated RatingBuyGBX 13
9/19/2017Peel HuntInitiated CoverageBuyGBX 13
8/31/2017N+1 SingerBoost Price TargetHoldGBX 8.70 ➝ GBX 10.20
8/31/2017Jefferies Financial GroupReiterated RatingBuyGBX 13
7/27/2017N+1 SingerBoost Price TargetHoldGBX 7.80 ➝ GBX 8.70
7/13/2017Shore CapitalReiterated Ratingnot rated
7/13/2017Jefferies Financial GroupReiterated RatingBuyGBX 13
7/6/2017N+1 SingerReiterated RatingHoldGBX 7.80
3/17/2017Jefferies Financial GroupReiterated RatingBuyGBX 8
3/16/2017N+1 SingerReiterated RatingHoldGBX 3.30
(Data available from 1/19/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/23/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/21/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/20/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/20/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/19/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Oxford Biomedica logo
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various diseases in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development stage include OXB-302 that targets haematological tumours with a CAR-T 5T4; OXB-203, which is in pre-clinical stage for the treatment of wet age-related macular degeneration; OXB-204, a lentiviral-based therapy for the ocular disease Leber's congenital amaurosis variant 10; OXB-103 (ALS) for central nervous system; and OXB-401 for liver indication. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. Oxford Biomedica plc has partnerships with Novartis, Bristol Myers Squibb, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, Santen Pharmaceutical Co Ltd, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Papyrus Therapeutics, Inc. to assess the impact and therapeutic benefit of PYTX-002, a gene replacement therapy to confer cellular pharmacy properties on a CAR-T cell therapy. It has a discovery collaboration with PhoreMost Limited to develop CAR-T cell therapies. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: GBX 973
Low: 957.20
High: 985

50 Day Range

MA: GBX 1,235.91
Low: 983
High: 1,506

52 Week Range

Now: GBX 973
Low: 922
High: 1,678

Volume

69,666 shs

Average Volume

127,774 shs

Market Capitalization

£838.01 million

P/E Ratio

44.03

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Oxford Biomedica?

The following Wall Street research analysts have issued stock ratings on Oxford Biomedica in the last year: Liberum Capital, Numis Securities Ltd, Peel Hunt, and Peel Hunt LLP.
View the latest analyst ratings for OXB.

What is the current price target for Oxford Biomedica?

4 Wall Street analysts have set twelve-month price targets for Oxford Biomedica in the last year. Their average twelve-month price target is GBX 1,707.50, suggesting a possible upside of 75.5%. Peel Hunt has the highest price target set, predicting OXB will reach GBX 2,150 in the next twelve months. Numis Securities Ltd has the lowest price target set, forecasting a price of GBX 1,200 for Oxford Biomedica in the next year.
View the latest price targets for OXB.

What is the current consensus analyst rating for Oxford Biomedica?

Oxford Biomedica currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OXB will outperform the market and that investors should add to their positions of Oxford Biomedica.
View the latest ratings for OXB.

What other companies compete with Oxford Biomedica?

How do I contact Oxford Biomedica's investor relations team?

Oxford Biomedica's physical mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company's listed phone number is +44-1865-783000. The official website for Oxford Biomedica is www.oxfordbiomedica.co.uk.